mirage

Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Pulido, Federico spa
dc.contributor.author Pérez-Valero, Ignacio spa
dc.contributor.author Delgado, Rafael spa
dc.contributor.author Arranz, Alberto spa
dc.contributor.author Pasquau, Juan spa
dc.contributor.author Portilla, Joaquín spa
dc.contributor.author Rubio, Rafael spa
dc.contributor.author González-García, Juan spa
dc.contributor.author Miralles, Pilar spa
dc.contributor.author Pérez-Elías, María J. spa
dc.contributor.author Ocampo, Antonio spa
dc.contributor.author Hernando Jeréz, María Asunción spa
dc.contributor.author Estrada, Vicente spa
dc.contributor.author Clotet, Bonaventura spa
dc.contributor.author Podzamczer, Daniel spa
dc.contributor.author Arribas, José R. spa
dc.date.accessioned 2013-11-27T17:26:15Z
dc.date.available 2013-11-27T17:26:15Z
dc.date.issued 2009 spa
dc.identifier.citation Pulido, F., Pérez-Valero, I., Delgado, R., Arranz, A., Pasquau, J., POrtílla, J., ..., & Arribas, J. R. (2009). Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antiviral Therapy, 14(2), 195-201. spa
dc.identifier.uri http://hdl.handle.net/11268/571
dc.description.abstract The objective of this studio was to analyze risk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as maintenance treatment have not been determined. In 121 patients enrolled in the OK and OK04 clinical trials assigned to receive monotherapy with LPV/r, we attempted to identify factors associated with loss of virological suppression at 48 weeks, defined as confirmed serum HIV type-1 RNA>50 copies/ml, with missing data or changes caused by toxicity censored. Univariate and multivariate Cox proportional hazard models were used to calculate hazard ratios for the risk of loss of virological suppression. At week 48, 15 patients experienced loss of virological suppression. Probability of loss of virological suppression was 12.7%. Less than 9 months of maintenance of virological suppression prior to monotherapy, a lower baseline haemoglobin and low adherence measured by self-reported total missed doses in the week prior to study visit were associated with loss of virological suppression in the univariate analyses. Independent factors associated with loss of virological suppression by multivariate analyses were > or =2 visits with self-reported missed doses in the week prior to the study visit, a lower baseline haemoglobin and a nadir CD4(+) T-cell count <100 cells/microl. In conclusion, suboptimal adherence, lower baseline haemoglobin and a nadir CD4(+) T-cell count <100 cells/microl were the main risk factors for losing virological suppression in patients randomized to monotherapy with LPV/r. spa
dc.language.iso eng spa
dc.title Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression spa
dc.type article spa
dc.description.impact 4.322 JCR (2009) Q1, 8/57 Infectious diseases, 33/237 Pharmacology & pharmacy, 6/30 Virology spa
dc.rights.accessRights closedAccess en
dc.subject.unesco Sida spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record